Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
T Bieber - Nature reviews Drug discovery, 2022 - nature.com
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …
Molecular mechanisms of atopic dermatitis pathogenesis
J Sroka-Tomaszewska, M Trzeciak - International journal of molecular …, 2021 - mdpi.com
Atopic dermatitis is a chronic, non-infectious inflammatory dermatosis. Acharacteristic
feature is persistent itching of the skin. The chronic, relapsing course of the disease …
feature is persistent itching of the skin. The chronic, relapsing course of the disease …
[HTML][HTML] Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies
K Papp, JC Szepietowski, L Kircik, D Toth… - Journal of the American …, 2021 - Elsevier
Background Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic
efficacy in a phase 2 study in adults with atopic dermatitis (AD). Objective To evaluate 8 …
efficacy in a phase 2 study in adults with atopic dermatitis (AD). Objective To evaluate 8 …
[HTML][HTML] Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …
interacting systems. In AD, skin inflammation is caused by host–environment interactions …
Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis
M Furue - International journal of molecular sciences, 2020 - mdpi.com
Atopic dermatitis (AD) is an eczematous, pruritic skin disorder with extensive barrier
dysfunction and elevated interleukin (IL)-4 and IL-13 signatures. The barrier dysfunction …
dysfunction and elevated interleukin (IL)-4 and IL-13 signatures. The barrier dysfunction …
[HTML][HTML] Pathophysiology of atopic dermatitis: Clinical implications
J Kim, BE Kim, DYM Leung - Allergy and asthma proceedings, 2019 - ncbi.nlm.nih.gov
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic
predisposition, epidermal barrier disruption, and dysregulation of the immune system are …
predisposition, epidermal barrier disruption, and dysregulation of the immune system are …
Subtypes of atopic dermatitis: From phenotype to endotype
Y Tokura, S Hayano - Allergology International, 2022 - jstage.jst.go.jp
abstract Atopic dermatitis (AD) is a heterogenous disorder and can be classified into
different types. Stratification of subtypes may enable personalized medicine approaches. AD …
different types. Stratification of subtypes may enable personalized medicine approaches. AD …
[HTML][HTML] Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
E Guttman-Yassky, R Bissonnette, B Ungar… - Journal of Allergy and …, 2019 - Elsevier
Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …
Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis
T Bieber - Allergy, 2020 - Wiley Online Library
Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …
[HTML][HTML] The aryl hydrocarbon receptor as a target of environmental stressors–Implications for pollution mediated stress and inflammatory responses
CFA Vogel, LS Van Winkle, C Esser… - Redox biology, 2020 - Elsevier
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor regulating the
expression of genes, for instance encoding the monooxygenases cytochrome P450 (CYP) …
expression of genes, for instance encoding the monooxygenases cytochrome P450 (CYP) …